by AnTolRx | Dec 15, 2020 | Publication
Kenison, J.E. et al. PNAS doi: 10.1073/pnas.2016451117. PMID: 33239445 (2020). by AnTolRx | Feb 24, 2020 | Updates
We are excited to announce that we will be presenting at the 3rd Antigen-Specific Immune Tolerance Drug Development conference. We will be discussing AnTolRx’s antigen-specific nanoformulation platform for the treatment of autoimmune diseases! Come join us in... by AnTolRx | Dec 4, 2019 | Updates
We are excited to attend the 38th annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 13th through the 16th. by AnTolRx | Nov 18, 2019 | Updates
We will be attending the symposium “New Frontiers in Therapies for Celiac Disease”. Join us at the University of Chicago (Chicago, IL) on November 23, 2019. by AnTolRx | Oct 29, 2019 | Updates
Psoriasis is an autoimmune disease that affects over 125 million people worldwide, that is up to 3% of the total population! At AnTolRx, our targeted approach actively promotes immune tolerance by inducing an anti-inflammatory phenotype and thus better treat disease....